This review outlines current diagnostic algorithms and pharmacological treatments for pulmonary hypertension, highlighting the roles of endothelin receptor antagonists and prostacyclins.
This review summarizes the current diagnostic and therapeutic strategies for managing idiopathic pulmonary arterial hypertension.
Current aspects of diagnosis, classification and therapy of pulmonary hypertension (PH) were reviewed in the article. A new classification, including all known clinical variants of PH, and functional classification were presented. A diagnostic algorithm with routine diagnostic methods and highly sensitive innovative techniques (CT-angiography of the lungs, perfusion scintigraphy, the right heart catheterization, etc.) was shown. The author discussed prognostic factors of 1-year survival, general pathogenic mechanisms including endothelin and prostacyclin pathways and a role of nitric oxide and soluble guanylate cyclase stimulators. Assessment criteria of acute vasoreactivity test results were reviewed. Typical therapeutic approaches including calcium channel blockers, oxygen, anticoagulants and diuretics were described. Main classes of specific drugs were listed such as endothelin receptor antagonists, prostacyclins, soluble guanylate cyclase stimulators, phosphodiesterase 5 inhibitors, selective prostacyclin receptor agonists. Current investigations are directed to searching new effective and safe drugs that could improve outcomes, slow down progression of the disease and improve quality of the patient’s life.
Н. А. Царева (Wed,) conducted a review in Pulmonary hypertension. Pharmacological treatment (endothelin receptor antagonists, prostacyclins, soluble guanylate cyclase stimulators, phosphodiesterase 5 inhibitors) was evaluated. This review outlines current diagnostic algorithms and pharmacological treatments for pulmonary hypertension, highlighting the roles of endothelin receptor antagonists and prostacyclins.